

## Confirmed Speakers

### Confirmed Speakers to date

#### Synthetic Organic Photochemistry in Batch and Flow



Prof. Kevin BOOKER-MILBURN  
(UNIVERSITY OF BRISTOL, Bristol, United Kingdom)

#### Making Molecular Prosthetics via Iterative Cross-Coupling with MIDA Boronates



Prof. Martin D. BURKE  
(UNIVERSITY OF ILLINOIS, Urbana, United States)

#### Oligonucleotide Synthesis Interfaced with Molecular Biology and Nanotechnology



Prof. Marvin CARUTHERS  
(UNIVERSITY OF COLORADO, Boulder, United States)

#### BETting on Epigenetic Targets : From Phenotypic Discovery to First Time in Man



Dr Chun-wa CHUNG  
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

#### Versatile Synthetic Methods: Access to Bioactive Molecules



Prof. Janine COSSY  
(ESPCI PARISTECH, Paris, France)

#### Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture



Dr Simona COTESTA  
(NOVARTIS, Basel, Switzerland)

#### Highly Anti-inflammatory Dendritic Polyglycerol Sulfates - a Multiple Target Approach



Prof. Rainer HAAG  
(FREE UNIVERSITY BERLIN, Berlin, Germany)

#### Targeting Protein Surfaces Using Designed Proteomimetics



Prof. Andrew HAMILTON  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

#### A New Approach to Tuberculosis Research: The Lilly TB Drug Discovery Initiative

## Confirmed Speakers



Dr Philip A. HIPSKIND  
(ELI LILLY & COMPANY, Indianapolis, United States)

### **Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to the Clinical Candidate AZD7687**



Dr Petra JOHANNESSON  
(ASTRAZENECA, Mölndal, Sweden)

### **Harnessing Synergy Between Natural Products and Synthesis Towards Drug Discovery**



Prof. Goverdhan MEHTA  
(UNIVERSITY OF HYDERABAD, Hyderabad, India)

### **New Strategies in Organic Synthesis: Recent Advances Based on Catalytic Reactions of Boron Reagents**



Prof. James P. MORKEN  
(BOSTON COLLEGE, Chestnut Hill, United States)

### **P2X Receptors: ATP-Gated Ion Channels as Novel Drug Targets**



Prof. Christa MÜLLER  
(UNIVERSITY OF BONN, Bonn, Germany)

### **Advances in Targeting Voltage-Gated Sodium Channels with Small Molecules**



Dr Antonio NARDI  
(GRÜNENTHAL, Aachen, Germany)

### **Organic Molecules as Biological Probes...an exciting journey**



Prof. Cristina NEVADO  
(UNIVERSITY OF ZURICH, Zurich, Switzerland)

### **Bitopertin (RG1678), a Potent and Selective Glycine Re-Uptake Inhibitor for the Treatment of Schizophrenia**



Dr Emmanuel PINARD  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

### **Antibody Drug Conjugates for the Treatment of Cancer**



Dr Paul POLAKIS  
(GENENTECH, San Francisco, United States)

## Confirmed Speakers

### Peptide Chemologics



Dr Lee ROBERTS  
(PFIZER, Sandwich, United Kingdom)

### The Discovery of the Macrocyclic HCV NS3/4A Protease Inhibitor MK-5172



Dr Michael ROWLEY  
(MERCK RESEARCH LABORATORIES, Kriens, Switzerland)

### The Design and Characterization of Targeted Covalent Inhibitors of Btk



Dr Eric SCHWARTZ  
(CELGENE AVIOMICS RESEARCH, Cambridge, United States)

### From Organic Synthesis to Biomedical Sciences - from Polyhydroxybutyrate (PHB) to Cell-Penetrating Peptides



Prof. Dieter SEEBACH  
(ETH ZURICH, Zürich, Switzerland)

### Engineering of Small Non-Antibody Protein Scaffolds as Novel Biopharmaceuticals: from Anticalins to PASylation



Prof. Arne SKERRA  
(TECHNICAL UNIVERSITY MUNICH, München, Germany)

### Metal Catalyzed Arylation of Nucleophiles



Dr Marc TAILLEFER  
(ENSCM, Montpellier, France)

### Discovery and Initial Clinical Results of [ $^{18}\text{F}$ ]-UCB-H, First PET Radiotracer Targeting Synaptic Vesicle 2A



Dr Anne VALADE  
(UCB, Braine-l'Alleud, Belgium)

## Confirmed Oral Communications

### EFMC Prize for a Young Medicinal Chemist in Academia Chemical Approaches to Biology and Therapeutics



Prof. Gonçalo BERNARDES  
(INSTITUTO DE MEDICINA MOLECULAR, PORTUGAL & UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

## Confirmed Speakers

### EFMC Prize for a Young Medicinal Chemist in Industry Free-Wilson and Structural Approaches to Co-Optimising Human and Rodent Isoform Potency for 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 (11 $\beta$ -HSD1) Inhibitors



Dr Frederick W. GOLDBERG  
(ASTRAZENECA, Macclesfield, United Kingdom)

### Novel Synthetic Chemical Chaperones as a New Basis For Amyotrophic Lateral Sclerosis (ALS) Treatment



Prof. Arie-Lev GRUZMAN  
(BAR ILAN UNIVERSITY, Ramat Gan, Israel)

### New Inhibitors of the Enzyme Isoprenylcysteine Carboxyl Methyltransferase (ICMT)



Prof. Maria del Mar MARTIN-FONTECHA  
(COMPLUTENSE UNIVERSITY OF MADRID, Madrid, Spain)

### Fragment-Based Design of Inhibitors of The Antituberculotic Target 1-Deoxy-D-Xylulose-5-Phosphate Synthase Exploiting an Innovative Combination of NMR Techniques



Mrs Tiziana MASINI  
(UNIVERSITY OF GRONINGEN, Groningen, The Netherlands)

### Design, Synthesis and Application Of Fluorinated Amino Acids as Labels to Study the Membrane Active Peptides by Solid State $^{19}\text{F}$ NMR



Dr Pavel MYKHAILIUK  
(ENAMINE LTD, Kyiv, Ukraine)

### Rapid Kinase SAR Generation: an Integrated Approach to Synthesis, Screening and Molecular Design



Dr David PARRY  
(CYCLOFLUIDIC LTD, United Kingdom)

### Virtual Screening and Design of New Pharmaceutical Agents Using PASS Approach



Prof. Vladimir POROIKOV  
(INSTITUTE OF BIOMEDICAL CHEMISTRY, Moscow, Russia)

### Discovery of Highly Potent S1P1 Receptor Antagonists with *in vivo* Efficacy



Dr Jean QUANCARD  
(NOVARTIS, Basel, Switzerland)

### Self-Immolative Spacers in Prodrug/Profluorophore Strategies: Determination of Kinetic Parameters for Release of Single or Multiple Substrates.

## Confirmed Speakers



Dr Frédéric SCHMIDT  
(INSTITUT CURIE, Paris, France)

### Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors



Dr Graeme SMITH  
(VERTEX PHARMACEUTICALS, Cambridge, United States)

### Synthetic Approach to Novel Melatonin Receptor Ligands



Mrs Maria VOLKOVA  
(MOSCOW STATE UNIVERSITY, CHEMISTRY DEPARTMENT, Moscow, Russia)